A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT07218341)
Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
Who can join: Review the eligibility criteria below.
Location: Mitchell Cancer Institute — Mobile, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (50 Sites)
Showing the first 25 of 50 sites.
- Mitchell Cancer Institute — Mobile, Alabama
- Arizona Oncology Associates, P.C. - HOPE — Tucson, Arizona
- Cancer Specialists, LLC — Jacksonville, Florida
- Minnesota Oncology Hematology, P.A. — Coon Rapids, Minnesota
- Cayuga Cancer Center — Ithaca, New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York — New York, New York
- Oncology Hematology Care Inc — Cincinnati, Ohio
- Texas Oncology - Paris — Fort Worth, Texas
- US Oncology - Texas Oncology — Kyle, Texas
- The Alfred Hospital — Melbourne,
- LKH - Universitätsklinikum der PMU Salzburg — Salzburg,
- AZ Delta — Roeselare,
- Princess Margaret Cancer Centre - University Health Network — Toronto,
- Xuanwu Hospital Capital Medical University — Beijing,
- Hunan Cancer Hospital — Changsha,
- Sun Yat-sen University Cancer Center — Guangdong,
- Nanfang Hospital of Southern Medical University — Guangzhou,
- Gansu Provincial Cancer Hospital — Lanzhou,
- The First Affiliated Hospital of Nanchang University — Nanchang,
- Fudan University Shanghai Cancer Center — Shanghai,
- Taizhou Hospital of Zhejiang Province — Taizhou,
- Hematology Hospital of the Chinese Academy of Medical Sciences — Tianjin,
- Tianjin Medical University Cancer Institute & Hospital — Tianjin,
- Affiliated Cancer Hospital of Xinjiang Medical University — Ürümqi,
- The Affiliated Hospital of Xuzhou Medical College — Xuzhou,
📞 Contact the Study Coordinator
Phone: (317) 615-4559
Email: LillyTrials@Lilly.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Lymphocytic Leukemia
- Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia — Houston, Texas
- Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia — Rochester, Minnesota
- A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) — Anchorage, Alaska
- Economic Analysis of Alliance A041202 CLL Study — Calgary, Alberta
- A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL — Chandler, Arizona
- Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) — Phoenix, Arizona
Explore by condition: All Chronic Lymphocytic Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.